摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Chloro-6,11-dihydrodibenzoxepin-11-one | 60086-50-2

中文名称
——
中文别名
——
英文名称
3-Chloro-6,11-dihydrodibenzoxepin-11-one
英文别名
3-chlorodibenzo[b,e]oxepin-11(6H)-one;3-chlorodibenzo[b,e]oxepine-11(6H)-one;3-chloro-11-keto-6,11-dihydrodibenz[b,e]oxepine;3-Chlorodibenzo[B,E]oxepin-11-one;3-chloro-6H-benzo[c][1]benzoxepin-11-one
3-Chloro-6,11-dihydrodibenz<b,e>oxepin-11-one化学式
CAS
60086-50-2
化学式
C14H9ClO2
mdl
——
分子量
244.677
InChiKey
AAXAGZNBGJOBKK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    423.5±45.0 °C(Predicted)
  • 密度:
    1.334±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    17
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    3-Chloro-6,11-dihydrodibenzoxepin-11-one 在 sodium tetrahydroborate 、 氯化亚砜 作用下, 以 甲醇 为溶剂, 反应 0.5h, 生成 3,11-Dichloro-6,11-dihydro-dibenzo[b,e]oxepine
    参考文献:
    名称:
    Synthesis and Biological Activity of 11-(4-(Cinnamyl)-1-piperazinyl)-6,11-dihydrodibenz(b,e)oxepin Derivatives, Potential Agents for the Treatment of Cerebrovascular Disorders.
    摘要:
    合成了一系列11-[4-(肉桂基)-1-哌嗪基]-6,11-二氢二苯并[b,e]氧芴及其相关化合物,并评价了它们对完全缺血、常压缺氧、脂质过氧化和惊厥的保护活性。通过对这一系列化合物的构效关系研究,发现了(E)-1-(3-氟-6,11-二氢二苯并[b,e]氧芑-11-基)-4-(3-苯基-2-丙烯基)哌嗪二马来酸盐(50),AJ-3941,它具有最适合的联合药理活性。
    DOI:
    10.1248/cpb.39.2564
  • 作为产物:
    描述:
    2-(溴甲基)苯甲酸乙酯 在 aluminum (III) chloride 、 氯化亚砜sodium ethanolate 、 sodium hydroxide 作用下, 以 乙醇二氯甲烷 为溶剂, 反应 8.75h, 生成 3-Chloro-6,11-dihydrodibenzoxepin-11-one
    参考文献:
    名称:
    二苯并[b,f] [1,4]氮杂ze庚因和二苯并[b,e] Oxepinesine:在H1R,H4R,5-HT2AR和其他选定的GPCR中,氯取代方式对药理学的影响。
    摘要:
    受到VUF6884(7-Chloro-11-(4-methylpiperazin-1-yl)dibenzo [b,f] [1,4] oxazep​​ine的启发),报道为双重H1 / H4受体配体(pKi:8.11(人H1R( hH1R)),7.55(人H4R(hH4R))),四种已知的和28种新的奥氮平及其相关的奥西平衍生物已合成,并在组胺受体和选定的胺能GPCR上进行了药理学表征。与奥氮平系列相反,在奥西平系列中,新化合物显示出对hH1R的高亲和力(pKi:6.8-8.7),但对hH4R的亲和力不高(pKi:≤5.3)。对于一种oxepine衍生物(1-(2-氯-6,11-二氢二苯并[b,e] oxepin-11-基] -4-甲基哌嗪),对映体被分离,R-对映体被鉴定为是对映体。 hH1R(pKi:8.83(R),7.63(S))和豚鼠H1R(gpH1R)(pKi:8.82(R),7.
    DOI:
    10.1016/j.phrs.2016.09.042
点击查看最新优质反应信息

文献信息

  • Synthesis and Biological Activity of 11-(4-(Cinnamyl)-1-piperazinyl)-6,11-dihydrodibenz(b,e)oxepin Derivatives, Potential Agents for the Treatment of Cerebrovascular Disorders.
    作者:Mikio KUROKAWA、Fuminori SATO、Yoshinobu MASUDA、Takayuki YOSHIDA、Yuko OCHI、Kayoko ZUSHI、Iwao FUJIWARA、Shunsuke NARUTO、Hitoshi UNO、Jun-ichi MATSUMOTO
    DOI:10.1248/cpb.39.2564
    日期:——
    A series of 11-[4-(cinnamyl)-1-piperazinyl]-6, 11-dihydrodibenz[b, e]oxepins and related compounds were synthesized and evaluated for their protective activities against complete ischemia, normobaric hypoxia, lipidperoxidation and convulsion. Structure-activity relationship studies of this series led to the finding of (E)-1-(3-fluoro-6, 11-dihydrodibenz[b, e]oxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine dimaleate (50), AJ-3941 with the most appropriate property for combined pharmacological activities.
    合成了一系列11-[4-(肉桂基)-1-哌嗪基]-6,11-二氢二苯并[b,e]氧芴及其相关化合物,并评价了它们对完全缺血、常压缺氧、脂质过氧化和惊厥的保护活性。通过对这一系列化合物的构效关系研究,发现了(E)-1-(3-氟-6,11-二氢二苯并[b,e]氧芑-11-基)-4-(3-苯基-2-丙烯基)哌嗪二马来酸盐(50),AJ-3941,它具有最适合的联合药理活性。
  • Metabolism of a novel skepinone l-like p38 mitogen-activated protein kinase inhibitor
    作者:K. Storch、M. Gehringer、B. Baur、S. A. Laufer
    DOI:10.1039/c4md00106k
    日期:——
    The p38 mitogen-activated protein kinase (MAPK) is a key mediator in cytokine-induced signaling events and is activated in response to a variety of extracellular stimuli such as stress factors, UV-light and inflammatory cytokines. Therefore, the p38 MAP kinase plays an integral role in disease states including oncogenesis, immune disorders and inflammatory processes. Recently a novel class of highly selective p38α inhibitors was described and characterized as tools and probes for in vivo studies. The objective of the current study was the preclinical characterization of 3-((2,4-difluorophenyl)amino)dibenzo[b,e]oxepin-11(6H)-one, a potent p38α MAP kinase inhibitor. In rat and human hepatic microsomal incubations, the examined compound is completely inactivated (concerning the inhibitory potency of the isolated p38α enzyme) by a CYP2B6 mediated phase 1 metabolism. The dehalogenation and subsequent hydroxylation in the para position of the 2,4-difluorophenyl residue was found to be the predominant transformation. The metabolite was detected in different quantities in both species. In a consecutive reaction the phase 1 metabolite conjugates with glucuronic acid in terms of a phase 2 metabolism. The responsible isoenzymes were identified to be UGT1A3, UGT1A9 and UGT1A10. In this reaction UGT1A10 is the predominant driver of the conversion. Similar to the phase 1 metabolite, the conjugate could also be found in different amounts in both examined species.
    p38 丝裂原激活蛋白激酶 (MAPK) 是细胞因子诱导的信号转导事件中的关键介质,并响应各种细胞外刺激(例如应激因子、紫外线和炎症细胞因子)而被激活。因此,p38 MAP 激酶在肿瘤发生、免疫紊乱和炎症过程等疾病状态中发挥着不可或缺的作用。最近,一类新型高选择性 p38α 抑制剂被描述和表征为体内研究的工具和探针。当前研究的目的是 3-((2,4-二氟苯基)氨基)二苯并[b,e]oxepin-11(6H)-one(一种有效的 p38α MAP 激酶抑制剂)的临床前表征。在大鼠和人肝微粒体孵育中,所检测的化合物通过 CYP2B6 介导的第 1 相代谢完全失活(考虑到分离的 p38α 酶的抑制效力)。发现 2,4-二氟苯基残基对位的脱卤和随后的羟基化是主要的转化。在两个物种中均检测到不同数量的代谢物。在连续反应中,第一相代谢物与葡萄糖醛酸结合,形成第二相代谢。相关同工酶被鉴定为 UGT1A3、UGT1A9 和 UGT1A10。在此反应中,UGT1A10 是转化的主要驱动力。与第一相代谢物类似,在两个受检物种中也发现了不同量的缀合物。
  • Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38α Inhibitors
    作者:Kathrin E. Martz、Angelika Dorn、Benjamin Baur、Verena Schattel、Márcia I. Goettert、Svenja C. Mayer-Wrangowski、Daniel Rauh、Stefan A. Laufer
    DOI:10.1021/jm300951u
    日期:2012.9.13
    The p38 MAP kinase is a key player in signaling pathways regulating the biosynthesis of inflammatory cytokines. Small molecule p38 inhibitors suppress the production of these cytokines. Therefore p38 is a promising drug target for novel anti-inflammatory drugs. In this study, we report novel dibenzepinones, dibenzoxepines, and benzosuberones as p38 alpha MAP kinase inhibitors. Previously reported dibenzepinones and dibenzoxepines were chemically modified by introduction of functional groups or removal of a phenyl ring. This should result in targeting of the hydrophobic region I, the "deep pocket", and the hinge glycine flip of the kinase. Potent inhibitors with IC50 values in the single digit nanomolar range (up to 3 nM) were identified. Instead of targeting the "deep pocket" in the DFG-out conformation, interactions with the DFG-motif in the in-conformation could be observed by protein X-ray crystallography.
  • US4086350A
    申请人:——
    公开号:US4086350A
    公开(公告)日:1978-04-25
  • Dibenzo[ b , f ][1,4]oxazepines and dibenzo[ b , e ]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H 1 R, H 4 R, 5-HT 2A R and other selected GPCRs
    作者:Franziska Naporra、Susanne Gobleder、Hans-Joachim Wittmann、Julia Spindler、Michael Bodensteiner、Günther Bernhardt、Harald Hübner、Peter Gmeiner、Sigurd Elz、Andrea Strasser
    DOI:10.1016/j.phrs.2016.09.042
    日期:2016.11
    lpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine), reported as a dual H1/H4 receptor ligand (pKi: 8.11 (human H1R (hH1R)), 7.55 (human H4R (hH4R))), four known and 28 new oxazepine and related oxepine derivatives were synthesised and pharmacologically characterized at histamine receptors and selected aminergic GPCRs. In contrast to the oxazepine series, within the oxepine series, the new compounds showed
    受到VUF6884(7-Chloro-11-(4-methylpiperazin-1-yl)dibenzo [b,f] [1,4] oxazep​​ine的启发),报道为双重H1 / H4受体配体(pKi:8.11(人H1R( hH1R)),7.55(人H4R(hH4R))),四种已知的和28种新的奥氮平及其相关的奥西平衍生物已合成,并在组胺受体和选定的胺能GPCR上进行了药理学表征。与奥氮平系列相反,在奥西平系列中,新化合物显示出对hH1R的高亲和力(pKi:6.8-8.7),但对hH4R的亲和力不高(pKi:≤5.3)。对于一种oxepine衍生物(1-(2-氯-6,11-二氢二苯并[b,e] oxepin-11-基] -4-甲基哌嗪),对映体被分离,R-对映体被鉴定为是对映体。 hH1R(pKi:8.83(R),7.63(S))和豚鼠H1R(gpH1R)(pKi:8.82(R),7.
查看更多